ARTL — Artelo Biosciences Income Statement
0.000.00%
Last trade - 00:00
- $4.32m
- -$6.10m
- 10
- 53
- 59
- 35
2019 August 31st | 2020 August 31st | 2021 August 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Total Operating Expenses | 3.21 | 4.69 | 7.44 | 10.3 | 9.93 |
Operating Profit | -3.21 | -4.69 | -7.44 | -10.3 | -9.93 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -2.17 | -4.65 | -7.44 | -10.1 | -9.29 |
Provision for Income Taxes | |||||
Net Income After Taxes | -2.17 | -4.65 | -7.44 | -10.1 | -9.29 |
Net Income Before Extraordinary Items | |||||
Net Income | -2.17 | -4.65 | -7.44 | -10.1 | -9.29 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -2.17 | -4.65 | -7.44 | -10.1 | -9.29 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -15 | -18.8 | -5.97 | -3.56 | -3.14 |